EP Patent

EP4397665A3 — Diaryl macrocycle polymorph

Assigned to Turning Point Therapeutics Inc · Expires 2024-08-21 · 2y expired

What this patent protects

This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotiidecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to composi…

USPTO Abstract

This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotiidecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans.

Drugs covered by this patent

Patent Metadata

Patent number
EP4397665A3
Jurisdiction
EP
Classification
—
Expires
2024-08-21
Drug substance claim
No
Drug product claim
No
Assignee
Turning Point Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.